Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

E

Vanda expects its operating cash spend to be approximately $3.8 million for the first quarter of 2009, including $0.8 million for severance payments. The projected $3 million of non-severance costs include administrative overhead, personnel costs, costs to complete an ongoing carcinogenicity study and regulatory consulting fees.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to ob
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Bed bugs compromised Penn State. A report ... Meanwhile, My Cleaning Products offered complimentary samples of its bed ... without using harmful chemical elements. , Based on the ... building was actually a dormitory , My Cleaning Products ... May 13 and bed bug presence was confirmed on May ...
(Date:5/23/2013)... DE (PRWEB) May 23, 2013 Just released ... by executive coach and author Barbara Roche: “Commit to Confidence: ... Out.” , Filled with helpful tips and quotes from the ... business leaders, and tangible exercises that readers can do on ... how to achieve their personal and professional goals. ...
(Date:5/22/2013)... 22, 2013 iLuv Creative Technology, the ... for the mobile lifestyle, announces they are now shipping ... manage multiple iPad devices efficiently. Winner of the 2013 ... Good Design award, MultiCharger-X is revolutionizing the way businesses, ... is deployed. , MultiCharger-X (iAD910) combines ...
(Date:5/22/2013)... May 22, 2013   Oligomerix, Inc. , ... disease modifying therapeutics for Alzheimer,s disease (AD) and ... its Series B financing, which includes both issuance ... would represent approximately $2.8M in new investments in ... supported the raise. Funding from ...
Breaking Biology Technology:Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... DIEGO, Nov. 4 ADVENTRX Pharmaceuticals,Inc. (Amex: ANX ... of ADVENTRX, is scheduled to present at the Rodman ... scheduled to present,on Tuesday, November 11th, 2008 at 2:50 ... place November 10-12, 2008 at the,Palace Hotel in New ...
... technology is one of the rapidly growing markets in life science ... is projected to reach $2.2 billion. Major factors that continue to ... the existing and emerging technologies. , ... San Jose, ...
Cached Biology Technology:Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Amplification Technologies Market to Reach $2.2 Billion by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:5/23/2013)... unnecessarily undergo surgery or harsh treatments because science ... aggressive forms of the disease. Researchers at Case ... are developing technology that allows patients to safely ... treatments or take drastic measures. , The project ... professor of biomedical engineering at Case Western Reserve ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
(Date:5/23/2013)... world,s largest and fastest growing open-access publishers, announces ... in Bioengineering and Biotechnology . , A ... in Bioengineering and Biotechnology will provide a ... and biotechnology research to be disseminated and discussed. ... will provide an open-science and interactive web ...
Breaking Biology News(10 mins):Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3First successful treatment of pediatric cerebral palsy with autologous cord blood 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... tripled in the last 25 years, putting many children at ... in Academic Pediatrics by an obesity expert at ... Center. "Children are not only becoming obese, but ... Skelton, M.D., lead author and director of the Brenner FIT ...
... Many experimental studies have found that physical exercise ... risks of cardiovascular disease; however, few of these ... ethnic breakdowns. Now, a long-term study of over ... gender- specific data on the cholesterol effects of ...
... from CSIRO,s Food Futures Flagship have made a breakthrough ... noses, (e-noses) by developing a system for comparing their ... fly. "Although e-noses already have many uses such ... air quality they are not as discriminating as ...
Cached Biology News:Research shows rates of severe childhood obesity have tripled 2Health benefits of physical activity more pronounced in women 2E-Noses: Testing their mettle against fly noses 2
Mouse monoclonal antibody raised against a partial recombinant ALAS2. NCBI Entrez Gene ID = ALAS2...
96-well format (For processing samples on microplate-size MALDI target plates such as those from Bruker, Shimadzu, Thermo, and PerkinElmer) Packaging: 2 / pack...
Mouse monoclonal antibody raised against a partial recombinant CENTB2. NCBI Entrez Gene ID = CENTB2...
...
Biology Products: